Loading clinical trials...
Loading clinical trials...
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Ensifentrine
Placebo
Locations
130
United States
Wright Clinical Research, LLC
Alabaster, Alabama, United States
SEC Clinical Research
Andalusia, Alabama, United States
Jasper Summit Research LLC
Jasper, Alabama, United States
Pulmonary Associates Clinical Trials
Phoenix, Arizona, United States
Elite Clinical Studies LLC
Phoenix, Arizona, United States
Clinical Research Institute of Arizona, LLC
Sun City West, Arizona, United States
Start Date
September 22, 2020
Primary Completion Date
May 3, 2022
Completion Date
July 6, 2022
Last Updated
October 16, 2023
NCT05746039
NCT07477600
NCT05878769
NCT06717659
NCT07274631
NCT05937854
Lead Sponsor
Verona Pharma plc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions